VRTX · PEAD → 0

Vertex Pharma reported Q3 2026 EPS of $4.21 on 2026-11-02, missing the $4.36 consensus by $0.15 (-3.4%).

Print-day reaction was -1.0% versus the prior close, a contained initial decline consistent with a modest EPS miss. The overnight gap to the T+1 open recovered +0.96%, suggesting the after-hours session partially absorbed the downside. Over the subsequent two trading days, VRTX drifted +2.2%, reversing the initial weakness and recouping most of the print-day loss. Cumulative abnormal return of +0.08% versus SPY.US over the three-day window is essentially flat, placing this squarely in PEAD neutral territory; the signal carries zero conviction through the holding window ending 2027-01-28.